RDS, led by Elie Lobel, has just raised €14 million to accelerate the rollout of its MultiSense® connected patch for post-operative monitoring in Europe and the US market. A long-standing partner of IHU Strasbourg, RDS illustrates the vitality of the healthcare innovation ecosystem within the Nexmed medical technology cluster.
A smart patch to transform post-operative patient monitoring
RDS (Advancing Patient Pathways™) is developing MultiSense®, a connected patch linked to a digital platform that can continuously measure six key physiological parameters (heart rate, respiratory rate, oxygen saturation, skin temperature, activity level, and posture).
Validated by several clinical studies and protected by more than 20 patents, this medical device aims to optimize the length of hospital stays and ensure patients’ safe return home. Since March 2024, MultiSense® has been CE marked and its rollout has already begun in around 15 establishments in France, Belgium, and Germany.*
Funding to accelerate European and international development
This Series A fundraising round, amounting to €14 million, will enable RDS to take several strategic steps:
- Strengthen its sales and support teams to meet growing demand in Europe;
- Deploy its industrial capabilities in France, with the ambition of contributing to French and European health sovereignty;
- Launch a medico-economic study (Sense-Eco) on more than 400 patients to objectively assess the impact of MultiSense® on post-operative length of stay and prepare for its reimbursement;
- Prepare for its entry into the North American market, with an FDA registration application planned for 2028.
This transaction brings the total funding raised by RDS to approximately €28 million. It was led by the SPI fund, managed by Bpifrance on behalf of the French government, and involves both new investors (Critical Path Ventures) and long-standing partners (MACSF, Capital Grand Est, etc.).
A success that reinforces the mission of the IHU Strasbourg
Founded in California and hosted by the IHU Strasbourg, RDS has been able to evolve in a stimulating environment where clinicians, researchers, and entrepreneurs collaborate to develop innovative medical solutions. The IHU promoted the first clinical trials to validate MultiSense® technology and included RDS in major collaborative projects with European partners (5G-OR and eCAP).
The IHU Strasbourg warmly congratulates Elie Lobel and his remarkable team for this achievement, which will help shape the future of connected health in Europe and beyond.
Visit the website: https://rdsdiag.com/en/
